Who are Dronabinol in Oral Dosage Form's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cannabis oil, Hemp, Cannabis Sativa Oil, Cannabis Extract Oil SR Capsule, MediCabilis CBD Oil, Moderate-Dose Cannabidiol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dronabinol-in-oral-dosage-form.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dronabinol in Oral Dosage Form — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dronabinol in Oral Dosage Form (Dronabinol in Oral Dosage Form) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid receptor agonist. Area: Oncology.

phase 3 Cannabinoid receptor agonist CB1 receptor, CB2 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dronabinol in Oral Dosage Form (Dronabinol in Oral Dosage Form) — Arbeitsgemeinschaft medikamentoese Tumortherapie. Dronabinol is a synthetic cannabinoid that acts as a partial agonist at cannabinoid receptors CB1 and CB2, modulating endocannabinoid signaling to produce therapeutic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dronabinol in Oral Dosage Form TARGET	Dronabinol in Oral Dosage Form	Arbeitsgemeinschaft medikamentoese Tumortherapie	phase 3	Cannabinoid receptor agonist	CB1 receptor, CB2 receptor
Cannabis oil	Cannabis oil	Assaf-Harofeh Medical Center	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
Hemp	Hemp	Thammasat University Hospital	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor, TRPV1, 5-HT1A receptor
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
Cannabis Extract Oil SR Capsule	Cannabis Extract Oil SR Capsule	University of Sao Paulo General Hospital	marketed	Cannabinoid receptor modulator	CB1 receptor, CB2 receptor
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Moderate-Dose Cannabidiol	Moderate-Dose Cannabidiol	Wayne State University	phase 3	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid receptor agonist class)

Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 drug in this class
AstraZeneca · 1 drug in this class
Montefiore Medical Center · 1 drug in this class
Shaare Zedek Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dronabinol in Oral Dosage Form — Competitive Intelligence Brief. https://druglandscape.com/ci/dronabinol-in-oral-dosage-form. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab